Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals and Sanofi announce that Dupixent has received European Commission approval for the treatment of eosinophilic esophagitis (EoE) in patients aged 12 and older. Dupixent is now the first targeted medicine available for this chronic inflammatory disease in the EU. In pivotal trials, 60% of patients treated with Dupixent experienced histological remission, significantly improving their swallowing abilities. The treatment shows potential in addressing other conditions related to type 2 inflammation. The safety profile remained consistent, with common side effects including injection site reactions and infections.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Dupixent® (dupilumab), recommending its approval to treat severe atopic dermatitis in children aged 6 months to 5 years. This decision is based on a successful Phase 3 trial showing Dupixent significantly improved skin clearance and reduced disease severity. Currently, about 80,000 children in Europe could benefit from this treatment. The final decision from the European Commission is pending.
On January 24, 2023, Regeneron Pharmaceuticals (NASDAQ: REGN) and Society for Science announced the finalists of the Regeneron Science Talent Search 2023, recognizing 40 high school seniors for their innovative scientific research. This prestigious competition, celebrating its 82nd year, awards over $1.8 million in prizes, with top awards reaching $250,000. The finalists, chosen from over 1,900 applicants, represent diverse scientific disciplines and address pressing societal issues such as climate change, public health, and social justice. The competition includes a rigorous judging process and culminates in an awards ceremony on March 14, 2023.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the date for its fourth quarter and full year 2022 financial results. The report will be released on February 3, 2023, prior to the U.S. market opening. A conference call and webcast to discuss the results will take place at 8:30 AM Eastern Time on the same day. Participants can join via the company's website or register for phone access. Regeneron focuses on developing innovative medicines, with a strong pipeline aimed at various serious diseases.
Regeneron Pharmaceuticals (NASDAQ: REGN) received marketing and manufacturing authorization from Japan's Ministry of Health for Libtayo® (cemiplimab), marking it as the first approved monotherapy for advanced cervical cancer in the country. This approval follows positive results from the Phase 3 EMPOWER-Cervical 1 trial, which showed significant survival benefits compared to chemotherapy. The global incidence of cervical cancer is rising, with about 600,000 new cases and 350,000 deaths each year. Libtayo was previously approved in the EU for similar indications.
Regeneron Pharmaceuticals and Sanofi announced that a Phase 3 trial of Dupixent (dupilumab) 300 mg weekly for treating eosinophilic esophagitis (EoE) showed significant improvements in patient histology and symptoms compared to placebo. Improvements were sustained for up to one year in patients aged 12 and older. Dupixent is the first U.S. approved targeted treatment for EoE. The FDA approved Dupixent in May 2022, and the EMA has given a positive opinion for its use in Europe. Safety results matched Dupixent's known profile, suggesting a favorable risk-benefit ratio.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:00 a.m. Pacific Time. Investors can access the presentation via the company's website, with an archived version available for 30 days thereafter. Regeneron, a leading biotechnology firm founded by physician-scientists, develops innovative medicines for serious diseases across various therapeutic areas including eye diseases, cancer, and rare conditions.
Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee has recommended Dupixent for approval to treat adolescents and adults aged 12 and over with eosinophilic esophagitis (EoE). This would make Dupixent the first targeted treatment for EoE in the EU, following its U.S. approval in May 2022. The positive recommendation is based on pivotal trial data showing significant improvements in patients' ability to swallow and histological remission. The European Commission will make a final decision soon.
Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved Dupixent (dupilumab) for treating adults with moderate-to-severe prurigo nodularis, marking it the first targeted medicine for this condition in Europe. Clinical trials showed that 60% of Dupixent patients experienced significant itch reduction at 24 weeks, compared to 18% for placebo. The drug also improved skin lesions and overall quality of life. Approximately 70,000 adults in Europe are affected by this chronic skin disease, underscoring the need for effective treatment options.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
What types of diseases does Regeneron Pharmaceuticals focus on?
What are some of Regeneron's key products?
Who are some of Regeneron's notable collaborators?
What recent financial steps has Regeneron taken?
How does Regeneron leverage genetic medicine?
What is the significance of Eylea in Regeneron's product portfolio?
What advancements has Regeneron made in gene therapy?
What is Dupixent used for?
What technologies does Regeneron use for drug development?
How does Regeneron contribute to scientific discovery?
